Skip to content
value.today

Elion Therapeutics, Inc.

Formerly Sfunga Therapeutics, Inc.

Total raised
$25 M
1 round on record
Latest round
$25 M
Jun 2024
First round on record
Jun 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Elion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$25 MNo. 1$10 to $50 million

Elion Therapeutics, Inc.: Raise no. 1, Jun 2024

Investors in this round

6 investors had bought by the notice of Jun 26, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $84 M offered; $58 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kieren Marr · Executive Officer, Director
  • Jim Flynn · Director
  • Jonathan Leff · Director
  • Martin Heidecker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Simansky, Assistant Corporate Secretary. Newest notice filed Jun 26, 2024. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Elion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Elion Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elion Therapeutics, Inc.
NameRoleNamed in
Kieren MarrExecutive officerJun 2024
Jim FlynnDirectorJun 2024
Jonathan LeffDirectorJun 2024
Kieren MarrDirectorJun 2024
Martin HeideckerDirectorJun 2024